What question did this study set out to answer?

To assess whether previously identified human monoclonal antibodies targeting the SARS-CoV-2 spike protein retain neutralization and therapeutic efficacy against the B.1.1.7 and B.1.351 variants.

August 21, 2021Cell ReportsOpen Access

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

View Full Paper

Ask AI

Bookmark

Authors

EMEfi MakdasiIsrael Institute for Biological Research AZAnat ZviIsrael Institute for Biological Research RARon AlcalayIsrael Institute for Biological Research

Discussion

Member takes

Implication

Preclinical study demonstrates neutralization and protection by monoclonal antibodies in transgenic mice, highlighting therapeutic resilience against emerging spike mutations.

Key Points

To assess whether previously identified human monoclonal antibodies targeting the SARS-CoV-2 spike protein retain neutralization and therapeutic efficacy against the B.1.1.7 and B.1.351 variants.
Evaluated binding and in vitro neutralization potencies of four receptor-binding domain (RBD) and two N-terminal domain (NTD) monoclonal antibodies against B.1.1.7 (Alpha) and B.1.351 (Beta) variants.
Tested therapeutic efficacy in vivo by treating K18-hACE2 transgenic mice with three selected monoclonal antibodies 2 days post-infection with each viral variant.
Monoclonal antibodies MD65 and BL6 maintained binding capacity to mutated RBD constructs associated with antibody escape.
In vivo administration of MD65 and BL6 provided effective protection against lethal challenge from both B.1.1.7 and B.1.351 variants in K18-hACE2 transgenic mice.

Cite This Study

Makdasi et al. (2021) studied this question.

synapsesocial.com/papers/6aab4ad00e910231d12bbef6 https://doi.org/10.1016/j.celrep.2021.109679

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates neutralization and protection by monoclonal antibodies in transgenic mice, highlighting therapeutic resilience against emerging spike mutations.

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

Discussion

Member takes

Implication

Key Points

Cite This Study

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider